Sign in

    Paysign Inc (PAYS)

    PAYS Q1 2025 Revenue Jumps 41%; Pharma Business Surges 261%

    Reported on May 9, 2025 (After Market Close)
    Pre-Earnings Price$2.71Last close (May 8, 2025)
    Post-Earnings Price$2.82Open (May 9, 2025)
    Price Change
    $0.11(+4.06%)
    • Robust Revenue and Profit Momentum: The company posted 41% year-over-year revenue growth to $18.6 million and a significant surge in net income (over 737% increase YoY) in Q1 2025, reflecting strong operational performance and a solid growth trajectory.
    • Accelerating Pharma Patient Affordability Business: The pharma segment grew by 261% YoY to $8.6 million, now representing 46.3% of quarterly revenues, which signals a high-growth, higher-margin revenue stream poised for further expansion in 2025.
    • Strategic Operational Synergies and Innovation: The acquisition of Gamma Innovation is already translating into operational efficiencies, with expected annual cash cost savings of $4–$5 million and positioning the company for new revenue streams across plasma and broader healthcare sectors.
    • Concerns over the plasma business performance: Revenues declined by 9.2% year-over-year with a reduction in revenue per plasma center to $6,517, indicating potential sustained headwinds from industry-wide supply surpluses and efficiency gains that may pressure future growth.
    • Rising operational expenses amid aggressive investments: SG&A expenses increased by 28.2% and total operating expenses by 27.8% due to substantial investments in IT and employee growth (increasing headcount from 132 to 190), which could pressure margins if revenue growth does not keep pace.
    • Integration risks from the Gamma acquisition: Although the acquisition is expected to save $4–$5 million in annual cash flow, early integration efforts and the challenge of aligning new technology with existing operations could temporarily disrupt efficiencies and add execution risk.
    MetricYoY ChangeReason

    Total Revenue

    Increased from $13.19M to $18.60M (41% YoY increase)

    The overall increase is primarily driven by a substantial surge in Pharma Industry revenue, which more than offset declines in other segments. Higher utilization of new patient affordability programs and increased claim processing in Q1 2025 contributed to this growth.

    Pharma Industry Revenue

    Increased from $2.389M to $8.62M (over 261% YoY increase)

    A major expansion in pharma programs—both from full-year impacts of initiatives launched previously and new program rollouts in Q1 2025—resulted in a significant increase in revenue. Increased claims processing and higher fee collections played key roles.

    Plasma Industry Revenue

    Decreased from $10.368M to $9.41M (9% decrease)

    Plasma revenue declined due to an industry-wide oversupply of plasma inventories leading to reduced plasma donations and lower performance per center when compared to the previous period. This decline contrasts with prior growth in plasma centers, highlighting market normalization.

    Other Revenue

    Increased from $0.433M to $0.57M

    Modest growth in Other revenue was observed, stemming from increased usage and growth in retail, payroll, and prepaid disbursement programs compared to the previous period. The incremental increase reflects continued but slower adoption relative to pharma initiatives.

    Net Income

    Increased from $309,096 to $2,586,100 (approximately 740% YoY increase)

    The dramatic rise in net income is linked to the robust growth in Pharma revenue, improved operating income, and significant scaling in fee and claim processing revenue—factors that starkly contrast with the modest performance in Q1 2024..

    Operating Income

    Turned from a loss of $258,352 in Q1 2024 to a positive $2,489,066 in Q1 2025

    Operating income improved significantly due to the operational turnaround driven by a surge in pharma-related revenues and better cost management, shifting the margin from negative to positive compared to the previous period..

    Operating Cash Flow

    Turned negative at –$6,033,177 in Q1 2025

    **Despite strong earnings, the negative operating cash flow reflects changes in working capital, including increases in accounts receivable and adjustments related to the timing of cash inflows from pharma programs versus end-of-period invoicing by third-party providers, contrasting previous positive flows. **

    Total Assets

    Increased from $179.03M to $205.12M (approximately 15% increase)

    Total assets grew due to higher accounts receivable and significant increases in intangible assets, indicating an expansion in revenue-generating activities and investments in proprietary technology relative to the previous period..

    Intangible Assets

    Increased from $12.24M to $25.15M (a 105% YoY increase)

    **The near doubling of intangible assets is attributable to major technology acquisitions (such as "Acquired tech" for $11,679,000 and a new non-compete asset for $567,000) and continued investments in the platform, marking a significant change from the previous period. **

    MetricPeriodPrevious GuidanceCurrent GuidanceChange

    Total Revenue

    FY 2025

    no prior guidance

    Expected to be in the range of $68.5 million to $70 million, reflecting year-over-year growth of 17.5% to 20%

    no prior guidance

    Plasma Revenue

    FY 2025

    no prior guidance

    Estimated to make up approximately 57.5% of total revenue

    no prior guidance

    Pharma Revenue

    FY 2025

    no prior guidance

    Expected to continue its growth of at least 100% year-over-year

    no prior guidance

    Gross Profit Margins

    FY 2025

    no prior guidance

    Expected to be between 62% and 64%

    no prior guidance

    Operating Expenses

    FY 2025

    no prior guidance

    Expected to be between $47.5 million and $50 million

    no prior guidance

    Depreciation and Amortization Exp.

    FY 2025

    no prior guidance

    Expected to be between $10.5 million and $11.5 million

    no prior guidance

    Stock-Based Compensation

    FY 2025

    no prior guidance

    Expected to be approximately $6 million

    no prior guidance

    Interest Income

    FY 2025

    no prior guidance

    Expected to be approximately $2.8 million

    no prior guidance

    Net Income

    FY 2025

    no prior guidance

    Expected to be approximately breakeven for the year

    no prior guidance

    Adjusted EBITDA

    FY 2025

    no prior guidance

    Expected to be in the range of $12.5 million to $13.5 million or $0.22 to $0.24 per diluted share

    no prior guidance

    Diluted Share Count

    FY 2025

    no prior guidance

    Estimated to be 56.5 million shares

    no prior guidance

    Total Revenue

    Q1 2025

    no prior guidance

    Expected to be in the range of $17.5 million to $18 million

    no prior guidance

    Patient Affordability Revenues

    Q1 2025

    no prior guidance

    Expected to be 40% to 45% of revenue for the quarter

    no prior guidance

    Gross Profit Margins

    Q1 2025

    no prior guidance

    Expected to be between 63% and 64%

    no prior guidance

    Operating Expenses

    Q1 2025

    no prior guidance

    Expected to be between $10.5 million and $11 million

    no prior guidance

    Depreciation and Amortization

    Q1 2025

    no prior guidance

    Expected to be approximately $1.9 million

    no prior guidance

    Stock-Based Compensation

    Q1 2025

    no prior guidance

    Expected to be approximately $2.1 million

    no prior guidance

    Adjusted EBITDA

    Q1 2025

    no prior guidance

    Expected to be in the range of $4 million to $5 million or 21.7% to 27.2% of revenue

    no prior guidance

    MetricPeriodGuidanceActualPerformance
    Total Revenue
    Q1 2025
    $17.5 million to $18 million
    $18.60 million
    Beat
    Patient Affordability Revenues
    Q1 2025
    40% to 45% of total revenue
    46.3% (8.62 ÷ 18.60)
    Beat
    Gross Profit Margin
    Q1 2025
    63% to 64%
    62.9% ((18,598,149 − 6,907,321) ÷ 18,598,149)
    Missed
    Operating Expenses
    Q1 2025
    $10.5 million to $11 million
    $9.20 million
    Beat
    Depreciation & Amortization
    Q1 2025
    Approximately $1.9 million
    $1.80 million
    Met